Newbridge Financial Services Group, Inc. Neurocrine Biosciences Inc Transaction History

Newbridge Financial Services Group, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Sep 11, 2024	SELL	$130.86 - $143.19 $654 - $715	-5 Reduced 20.0%	20 $2,000
Q1 2024 Apr 24, 2024	BUY	$130.4 - $143.74 $652 - $718	5 Added 25.0%	25 $3,000
Q4 2023 Mar 28, 2024	SELL	$106.07 - $132.76 $4,773 - $5,974	-45 Reduced 69.23%	20 $2,000
Q2 2022 Jul 15, 2022	SELL	$75.79 - $100.07 $2,273 - $3,002	-30 Reduced 31.58%	65 $6,000
Q3 2021 Oct 27, 2021	SELL	$86.18 - $99.03 $86 - $99	-1 Reduced 1.04%	95 $9,000
Q1 2021 Sep 07, 2021	BUY	$87.57 - $119.4 $4,028 - $5,492	46 Added 92.0%	96 $9,000
Q3 2020 Sep 07, 2021	BUY	$96.16 - $135.15 $4,808 - $6,757	50 New	50 $5,000

652

96.5M

282K

281K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $10.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.